EGFR and cancer: Overexpression, amplification and mutations of ErbBs are frequently associated with carcinogenesis and malignant progression in many types of human cancers; therefore, anti-ErbB inhibitors have been developed as targeted anti-cancer drugs6, 7, 8, 9, 10, 11.